2019
Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review
Waldman R, Strober B. Laboratory monitoring requirements during mycophenolate mofetil therapy for dermatologic conditions: A single-institution retrospective chart review. Journal Of The American Academy Of Dermatology 2019, 85: 726-728. PMID: 30797844, DOI: 10.1016/j.jaad.2019.02.040.Peer-Reviewed Original ResearchDrug Therapy, CombinationHumansImmunosuppressive AgentsLaboratoriesMycophenolic AcidPrednisoneRetrospective StudiesJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal Of The American Academy Of Dermatology 2019, 80: 1029-1072. PMID: 30772098, DOI: 10.1016/j.jaad.2018.11.057.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisAAD-NPF GuidelinesInflammatory multisystem diseaseImportant clinical questionsBiologic agentsPsoriasis managementMultisystem diseaseTreatment recommendationsClinical questionsUS populationPsoriasisAvailable evidenceCareTreatmentGuidelinesPatientsDermatologistsDiseaseBiologics
2016
Why Biologic Therapies Sometimes Lose Efficacy.
Strober B. Why Biologic Therapies Sometimes Lose Efficacy. Seminars In Cutaneous Medicine And Surgery 2016, 35: s78-80. PMID: 27525443, DOI: 10.12788/j.sder.2016.022.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabBiological ProductsClinical Trials as TopicDermatologic AgentsDrug Therapy, CombinationEvidence-Based MedicineHumansImmunosuppressive AgentsPsoriasisTreatment OutcomeTreatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2015
The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald J, Klufas D, Strober B. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. Journal Of Drugs In Dermatology 2015, 14: 888-92. PMID: 26267735.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCyclosporineDermatologic AgentsDrug Therapy, CombinationEtanerceptFemaleFoot DermatosesHand DermatosesHumansImmunosuppressive AgentsInfliximabMaleMethotrexateMiddle AgedMycophenolic AcidPsoriasisSeverity of Illness IndexThalidomideUstekinumabYoung Adult
2012
A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
Gottlieb A, Langley R, Strober B, Papp K, Klekotka P, Creamer K, Thompson E, Hooper M, Kricorian G. A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. British Journal Of Dermatology 2012, 167: 649-657. PMID: 22533447, PMCID: PMC3504074, DOI: 10.1111/j.1365-2133.2012.11015.x.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisCombination therapyAdverse eventsWeek 24Etanercept monotherapyMonotherapy groupPlaque psoriasisWeek 12Necrosis factor inhibitor therapyStatic Physician's Global AssessmentGlobal assessmentMethotrexate combination therapyPhysician global assessmentPlacebo-controlled studySerious adverse eventsCombination therapy groupProportion of patientsAddition of methotrexatePASI 50PASI 75PASI 90Primary endpointSevere psoriasisAcceptable tolerabilityPsoriasis Area
2007
Alefacept for the treatment of psoriasis and other dermatologic diseases
Strober B, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatologic Therapy 2007, 20: 270-276. PMID: 17970892, DOI: 10.1111/j.1529-8019.2007.00140.x.Peer-Reviewed Original ResearchMeSH KeywordsAlefaceptDrug Therapy, CombinationHealth Care CostsHumansPsoriasisRecombinant Fusion ProteinsSkin DiseasesConceptsT cellsSeverity Index (PASI) 75 responseMemory effector T cellsNovel biologic agentsLong-term remissionEffector T cellsTreatment of psoriasisAntigen presenting cellsPathophysiology of psoriasisCourse of therapyDimeric fusion proteinPASI 75Plaque psoriasisAdverse eventsPsoriasis AreaBiologic agentsMore patientsLabel useImmunologic activationPresenting cellsIntramuscular injectionDosing strategiesAlefaceptDermatologic diseasesPsoriasis
2006
Conventional systemic agents for psoriasis. A systematic review.
Strober B, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. The Journal Of Rheumatology 2006, 33: 1442-6. PMID: 16724368.Peer-Reviewed Original Research
2005
Folate supplementation during methotrexate therapy for patients with psoriasis
Strober B, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. Journal Of The American Academy Of Dermatology 2005, 53: 652-659. PMID: 16198787, DOI: 10.1016/j.jaad.2005.06.036.Peer-Reviewed Original ResearchMeSH KeywordsDrug Therapy, CombinationFolic AcidGastrointestinal TractHematinicsHumansImmunosuppressive AgentsLeucovorinMethotrexatePsoriasisConceptsFolate supplementationSide effectsMethotrexate therapyFolinic acidFolic acidUse of methotrexateEfficacy of methotrexateIncidence of hepatotoxicityTreatment of psoriasisSignificant side effectsUse of folateGastrointestinal intoleranceFolate supplementsInflammatory conditionsMEDLINE searchClinical experiencePatientsMethotrexateFolate antagonistTherapySupplementationSearch termsPsoriasisEfficacyToxicity
2004
Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober B, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Journal Of Drugs In Dermatology 2004, 3: 270-2. PMID: 15176161.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticCyclosporineDose-Response Relationship, DrugDrug Therapy, CombinationEtanerceptFemaleHumansImmunoglobulin GKeratolytic AgentsMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRecombinant Fusion ProteinsConceptsTumor necrosis factorTumor necrosis factor receptorWeekly doseRheumatoid arthritisPatients of psoriasisPlacebo-controlled studySevere plaque psoriasisSelf-administered medicationsJuvenile rheumatoid arthritisTreatment of psoriasisHuman fusion proteinNecrosis factor receptorPlaque psoriasisContinuous therapyPsoriasis AreaPsoriatic arthritisSystemic therapyPsoriasis patientsTreatment regimenClinical efficacyCombination therapyMedical historyClinical trialsNecrosis factorEtanercept